Read More Pharma Industry News CANbridge doses first patient in phase 2 EMBARK study of CAN108 in BA CANbridge Pharmaceuticals has dosed the first patient in the phase 2 EMBARK study of CAN108 (maralixibat) in biliary… bySrinathJuly 17, 2022